Advanced Modular Reactor (AMR) Feasibility and Development Project
Details of the 2-phase Advanced Modular Reactor Feasibility and Development Project.
Documents
Details
BEIS is investing up to £44 million in the Advanced Modular Reactor (AMR) feasibility and development (F&D) project. Advanced Modular Reactor (AMRs), here defined as a broad group of advanced nuclear reactors, differ from conventional reactors, which use pressurised or boiling water for primary cooling. They aim to maximise the amount of off-site factory fabrication and can target:
- generating low cost electricity
- increased flexibility in delivering electricity to the grid
- increased functionality, such as the provision of heat output for domestic or industrial purposes, or facilitating the production of hydrogen
- alternative applications that may generate additional revenue or economic growth
Phase 1
Phase 1 provided funding of up to £4 million to undertake a series of feasibility studies for AMR designs, with contracts worth up to £300,000.
The following 8 organisations were awarded contracts to produce feasibility studies as part of phase 1 of the AMR F&D project:
- Advanced Reactor Concepts LLC
- DBD Limited
- Blykalla Reaktorer Stockholm AB (LeadCold)
- Moltex Energy Limited
- Tokamak Energy Ltd
- U-Battery Developments Ltd
- Ultra Safe Nuclear Corporation
- Westinghouse Electric Company UK
Each organisation provided an abstract summarising their proposal (the claims and opinions expressed in the abstracts are those of the applicant organisation and don바카라 사이트™t necessarily reflect the official policy or position of BEIS).
Phase 2
Subject to phase 1 demonstrating clear value for money and government approval, a share of up to £40 million was available for selected projects from phase 1 to undertake development activities. A possible further £5 million was also made available to regulators to support this.
The 3 successful projects for Phase 2 were:
- Tokamak Energy
- Westinghouse
- U-Battery
Attached is a brief description of each project.